|

Unlocking the Power of Vitamin A: Tretinoin Enhances Cancer Treatment

ByHolly Zink
Unlocking the Power of Vitamin A: Tretinoin Enhances Cancer Treatment

Tretinoin is a derivative of vitamin A. It shows the potential to enhance the effects of chemotherapy. Combining tretinoin with chemotherapy improved survival rates in mesothelioma in mice.

Chemotherapy Response in Mesothelioma

Mesothelioma is a rare type of cancer that is hard to diagnose and treat. It develops from the thin layer of tissue that covers many of the body’s internal organs. Mesothelioma is caused by exposure to a toxic mineral called asbestos.

In most cases, doctors will use more than one type of treatment to remove as many cancer cells as possible from a patient’s body. The standard therapies include chemotherapy, radiation, and surgery.

When a patient gets chemotherapy treatment, they are given drugs that kill cells by damaging their DNA. Currently, the only FDA-approved chemotherapy for mesothelioma is a combination of pemetrexed and cisplatin.

Cisplatin is a platinum-based drug. It damages the DNA of dividing cells and slows down the growth of cancer cells. Doctors have noticed that in some cases, cancer cells become resistant to cisplatin. This makes the treatment less effective.

Vitamin A Improves Cancer Treatment

Chemotherapy is commonly used to treat advanced cancers. But it is often not curative and can have severe side effects. Immune checkpoint therapy boosts the body’s immune response against cancer. It has shown promise in improving outcomes. But, not all patients respond to this treatment, and it can cause serious side effects.

In a new study, researchers looked at drugs that could enhance the anti-cancer effects of chemotherapy. They found that tretinoin could improve the response to chemotherapy. It creates an environment within the tumor that is more sensitive to chemotherapy. It increases the presence of immune cells called CD8+ T cells in the tumor. These are known to be important for fighting cancer.

The combination of tretinoin and chemotherapy was effective in mesothelioma. But it did not show the same benefit in other types of cancer cells tested.

Overall, tretinoin shows promise as a potential adjunct to chemotherapy in mesothelioma. More research is needed to understand the potential of this treatment in clinical settings.

Source:

Tilsed, Caitlin M., M. Lizeth Orozco Morales, Rachael M. Zemek, Brianna A. Gordon, Matthew J. Piggott, Anna K. Nowak, Scott A. Fisher, Richard A. Lake, and W. Joost Lesterhuis. “Tretinoin Improves the Anti-Cancer Response to Cyclophosphamide, in a Model-Selective Manner.” BMC Cancer 24, no. 1 (December 2024): 1–11. https://doi.org/10.1186/s12885-024-11915-5.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Chemical in Wine May Improve Mesothelioma Treatment

    ByAlex Strauss

    There’s new evidence that a compound found in red wine may help improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma. Last year, a team of Korean researchers released the world’s first study on the mesothelioma-fighting power of resveratrol, a natural phenol derived from the skin of red grapes and found in red wine and grape juice. Now, the same team says resveratrol also appears to enhance the chemosensitivity of malignant mesothelioma cells. Study author Yoon-Jin Lee and colleagues discovered  a synergistic cancer-fighting effect in mesothelioma cells treated with both resveratrol and clofarabine, a prescription drug often used to treat acute lymphoblastic leukemia. Together, resveratrol and clofarabine “induced a strong cytotoxic effect” by influencing levels of the tumor suppressor,…

  • | |

    Mesothelioma Surgery May Have Added Benefit

    ByAlex Strauss

    Cancer researchers at Wake Forest University have found another benefit to the cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) combination used to treat peritoneal mesothelioma and other abdominal cancers: the control of fluid buildup. Fluid accumulation in the abdomen because of peritoneal mesothelioma or another type of cancer is known as ascites. Left untreated, ascites can cause bloating, discomfort, disfiguration, and shortness of breath when it interferes with the movement of the diaphragm. While patients with peritoneal mesothelioma, an aggressive cancer of the peritoneal surface, can have this fluid drained off, it often reaccumulates. But the new Wake Forest research suggests that CRS/HIPEC may offer a more permanent solution. Fifteen percent of the cancer patients in the study had…

  • | |

    Mesothelioma Study Cites Risks & Benefits of Second Surgery

    ByAlex Strauss

    Peritoneal mesothelioma patients who have cytoreductive surgery (CRS) and heated chemotherapy can sometimes benefit from a second surgery, but it may be harder the second time around. Researchers in France have recently published their findings in a study of patients with mesothelioma and other peritoneal cancers who experienced recurrence after  cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Peritoneal mesothelioma is an asbestos-related malignancy that spreads across the peritoneum, the membrane that lines the abdomen. For patients who are healthy enough to undergo it, cytoreductive surgery to remove as much of the cancer as possible, followed by a solution of heated chemotherapy drugs, has been shown to improve survival. But the French team wanted to examine the possible options for people…

  • |

    Mesothelioma Symptoms May Benefit from Tuberculosis Drugs

    ByAlex Strauss

    Pleural effusion is the one of most uncomfortable and life-limiting symptoms of pleural mesothelioma. The buildup of fluid in the pleural space around the lungs, which can happen in late stage mesothelioma as well as several other types of cancer, limits breathing and can be painful. Effusion is often one of the primary reasons that mesothelioma patients in the late stages of the disease have trouble taking a full breath and complain of chest pain and fatigue. While pleural fluid can be drained off through thoracentesis or chemically absorbed through pleurodesis, these treatments are painful, risky, and not always effective. Now, a team of researchers in China say they may have discovered a non-invasive method for dealing with pleural effusion caused…